High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Top Cited Papers
- 21 October 2010
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (11) , 1036-1047
- https://doi.org/10.1016/s1470-2045(10)70229-1
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional ExperienceJournal of Clinical Oncology, 2009
- Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphomaNeurology, 2007
- Primary central nervous system lymphoma – Biological aspects and controversies in managementEuropean Journal Of Cancer, 2007
- High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS LymphomaJournal of Clinical Oncology, 2006
- NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final reportAnnals of Neurology, 2005
- High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphomaAnnals of Oncology, 2005
- Response to chemotherapy and treating institution predict survival in primary central nervous system lymphomaBritish Journal of Haematology, 2004
- Is Withdrawal of Consolidation Radiotherapy an Evidence-Based Strategy in Primary Central Nervous System Lymphomas?Journal of Clinical Oncology, 2004
- Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor GroupJournal of Clinical Oncology, 2003
- Decreasing incidence rates of primary central nervous system lymphomaCancer, 2002